Last Update 02 Mar 26

Fair value Decreased 3.74%

EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery

Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.

Analyst Commentary

Recent Street research around Exact Sciences has included at least one downgrade, even as some peers in adjacent healthcare names have seen more upbeat revisions. In that context, the modest trim in fair value to $112.11 suggests a more balanced stance, with valuation work reflecting updated assumptions rather than a wholesale change in opinion on the business.

Goldman Sachs has also adjusted its view on a related diagnostics name, Abbott, citing a period where fundamental trends and share performance did not align. For Exact Sciences, it is notable that Goldman states its current model for Abbott does not incorporate the pending acquisition of Exact Sciences. As a result, many published Abbott forecasts may not yet fully reflect any impact from that deal structure or timing.

For you as an investor, this mix of caution and recalibration indicates that sentiment on Exact Sciences is active and evolving, with both upside and downside angles under review. The trimmed fair value estimate sits within that context and ties updated profit margin expectations and a lower future P/E assumption together into a single, more conservative benchmark.

Bullish Takeaways

Bullish analysts in related healthcare names are still lifting price targets, which signals ongoing interest in diagnostics and medical technology as investable themes, even if Exact Sciences itself has faced a downgrade.
Goldman Sachs explicitly notes that its Abbott model excludes the pending acquisition of Exact Sciences, which implies there is potential for future model updates once deal terms and integration assumptions are fully reflected.
The revised fair value of $112.11 for Exact Sciences, while slightly lower, still incorporates a higher profit margin outlook, indicating that some positive expectations around execution and cost discipline remain in analyst models.
Ongoing Street coverage of transactions involving Exact Sciences keeps the name on the radar for institutional research teams, which can support continued scrutiny of valuation, growth drivers and operational delivery.

What's in the News

The Oncotype DX Breast Recurrence Score test has now been used by more than 2 million breast cancer patients worldwide to guide treatment decisions, reflecting over two decades of clinical use and broad adoption in more than 100 countries. (Company announcement)
Exact Sciences reports that the Oncotype DX test is the only genomic assay proven to predict adjuvant chemotherapy benefit in early stage HR+, HER2- breast cancer and holds a Category 1A recommendation in the NCCN Clinical Practice Guidelines. (Company announcement)
The company estimates that use of the Oncotype DX test has spared around 1.6 million patients from potentially unnecessary chemotherapy and, based on a published economic model, has resulted in average lifetime savings of about US$10,000 per patient in the US healthcare system. (Company announcement)
First clinical study results for the Oncodetect MRD test in early triple negative breast cancer show that post surgery ctDNA positivity was associated with a much higher risk of distant recurrence, with 95% of MRD negative patients remaining free of distant recurrence at 3 years in the analyzed group. (NSABP B-59 substudy data)
Exact Sciences plans to submit the Oncodetect MRD data to a peer reviewed journal and to MolDx in support of Medicare coverage, while also collaborating on NSABP B-64, a large registry trial targeting 1,800 participants across breast cancer subtypes. (Company announcement)

Valuation Changes

Fair Value: trimmed from $116.46 to $112.11, a small reduction in the modeled equity value per share.
Discount Rate: adjusted slightly from 7.29% to 7.26%, indicating a very modest change in the implied risk or required return used in the model.
Revenue Growth: revised from 15.95% to 14.93%, reflecting a slightly lower assumed pace of future dollar revenue expansion in the forecast period.
Net Profit Margin: nudged up from 9.98% to 10.20%, pointing to a modestly stronger earnings contribution from each dollar of sales in the model.
Future P/E: brought down from 60.31x to 54.19x, indicating a lower valuation multiple applied to expected earnings in the outer years.

1 view

Key Takeaways

Faster-than-expected adoption of new products and AI-driven patient engagement may drive earlier and stronger recurring revenue and margin improvements than anticipated.
Expansion into multi-cancer detection and blood-based diagnostics, combined with operational efficiencies, positions the company for leadership in diagnostics and sustained higher profitability.
Overdependence on Cologuard and costly expansion efforts, amid intensifying competition and reimbursement uncertainty, threaten long-term revenue stability and market leadership.

Catalysts

About Exact Sciences

Provides cancer screening and diagnostic test products in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Whereas analyst consensus expects the Cologuard Plus ramp to be mainly back-half weighted and gradual due to payer coverage phasing in, the accelerated commercial execution, record-breaking provider adoption, and surge in brand awareness could drive much faster adoption and earlier revenue upside than currently modeled.
Analyst consensus sees rescreening and care gap programs as incremental; however, the company's real-time ability to convert unscreened and rescreen-eligible patients using AI-driven digital engagement and a rapidly expanding provider network suggests that recurring high-margin revenue streams will outpace expectations and structurally lift net margins over the long term.
With multi-cancer early detection (MCED) launching through an unrivaled national commercial infrastructure, Exact Sciences is positioned to capture outsized share of a $25 billion largely untapped market, leveraging powerful secular tailwinds from an aging population and a rapidly growing emphasis on preventive healthcare, with correspondingly transformative impact on future revenue growth.
The multi-year productivity plan focused on AI-powered automation, operational streamlining, and scale efficiencies is on track to drive more than $150 million of annualized cost savings by 2026, likely resulting in adjusted EBITDA margins that could outpace the company's current long-term targets and meaningfully expand long-term earnings power.
Strategic flexibility through portfolio expansion-including the exclusive Freenome blood-based CRC test and a robust pipeline supported by deep payer, provider, and health system relationships-positions Exact Sciences to be a one-stop leader in next-gen cancer diagnostics, potentially establishing long-term pricing power and higher gross margins as industry consolidation accelerates.

Exact Sciences Earnings and Revenue Growth

Exact Sciences Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Exact Sciences compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Exact Sciences's revenue will grow by 14.4% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from -34.2% today to 15.4% in 3 years time.
The bullish analysts expect earnings to reach $677.9 million (and earnings per share of $3.4) by about September 2028, up from $-1.0 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 28.4x on those 2028 earnings, up from -10.4x today. This future PE is greater than the current PE for the US Biotechs industry at 15.3x.
Analysts expect the number of shares outstanding to grow by 2.29% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.07%, as per the Simply Wall St company report.

Exact Sciences Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Exact Sciences remains heavily dependent on the Cologuard franchise, and while Cologuard Plus is showing some early momentum and payer adoption, the company's limited diversification means that any stagnation, reimbursement cuts, or advances in competing technologies for stool-based testing could introduce significant revenue and earnings volatility over the long term.
Escalating investment in R&D and M&A to broaden the portfolio-such as the recent Freenome licensing and past acquisitions like Thrive-has delivered uncertain ROI, with recent internal efforts (especially for blood-based screening) failing to deliver breakthrough results and margins currently supported by aggressive productivity plans; failure to deliver commercially-successful products from these expensive initiatives could strain operating margins and net income.
Intensifying competition from both major diagnostics companies and nimble startups in CRC screening, notably with the rise of new blood-based and multi-cancer early detection technologies such as Guardant's Shield, poses a risk to Exact's market share, slows growth, and could drive down pricing, ultimately compressing future revenues and net margins.
Exact's financial and commercial focus has traditionally been built on achieving and maintaining premium pricing and wide adoption, but ongoing reimbursement and healthcare cost pressures-including the risk that blood-based or other emerging tests may not achieve guideline inclusion or broad payer coverage-add significant uncertainty to long-term revenue growth and profitability.
The company's core growth strategies rely on acquisition and third-party licensing (e.g., Freenome), which may erode proprietary competitive advantages and give external partners (like Freenome) access to Exact's customer base and real-world data, potentially speeding up competitor advancement in multi-cancer and advanced diagnostics, and threatening future topline growth and earnings as the competitive moat weakens.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Exact Sciences is $77.68, which represents two standard deviations above the consensus price target of $63.14. This valuation is based on what can be assumed as the expectations of Exact Sciences's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $50.0.
In order for you to agree with the bullish analysts, you'd need to believe that by 2028, revenues will be $4.4 billion, earnings will come to $677.9 million, and it would be trading on a PE ratio of 28.4x, assuming you use a discount rate of 7.1%.
Given the current share price of $55.41, the bullish analyst price target of $77.68 is 28.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Exact Sciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

AI And Genomics Will Expand Screening For Aging Markets